BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38855496)

  • 21. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
    Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
    Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives.
    Mosconi C; Cappelli A; Pettinato C; Golfieri R
    World J Hepatol; 2015 Apr; 7(5):738-52. PubMed ID: 25914774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
    Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
    Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients.
    Chung SW; Cho H; Shin H; Park J; Kim JY; Hong JH; Hur MH; Park MK; Lee YB; Yu SJ; Lee M; Kim YJ; Paeng JC; Yoon JH; Chung JW; Lee JH; Kim HC
    Front Oncol; 2023; 13():1081479. PubMed ID: 36925930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma.
    Demirtas CO; D'Alessio A; Rimassa L; Sharma R; Pinato DJ
    JHEP Rep; 2021 Oct; 3(5):100347. PubMed ID: 34505035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
    J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; DechĂȘne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma.
    Khalid MA; Achakzai IK; Hanif FM; Ahmed S; Majid Z; Luck NH
    Gastroenterol Hepatol Bed Bench; 2019; 12(2):110-115. PubMed ID: 31191834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma.
    Aujay G; Etchegaray C; Blanc JF; Lapuyade B; Papadopoulos P; Pey MA; Bordenave L; Trillaud H; Saut O; Pinaquy JB
    Diagn Interv Imaging; 2022; 103(7-8):360-366. PubMed ID: 35183483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 36. The Deterioration of Sarcopenia Post-Transarterial Radioembolization with Holmium-166 Serves as a Predictor for Disease Progression at 3 Months in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study.
    Trobiani C; Ubaldi N; Teodoli L; Tipaldi MA; Cappelli F; Ungania S; Vallati G
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma.
    Vardar BU; Meram E; Karaoglu K; Liang M; Yu M; Laeseke P; Ozkan OS
    Cureus; 2022 Apr; 14(4):e23783. PubMed ID: 35518553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy.
    Feng R; Cheng DX; Song T; Chen L; Lu KP
    World J Gastrointest Surg; 2023 Apr; 15(4):687-697. PubMed ID: 37206075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.